Reason for request
Inclusion on list of products for hospital use.
Clinical Benefit
| Substantial |
The actual benefit of ACTILYSE 2 mg is substantial. |
Clinical Added Value
| minor |
ACTILYSE 2 mg provides a minor improvement in actual benefit (IAB IV) in terms of efficacy in comparison with ACTOSOLV UROKINASE. |
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
JZBLKKXQCMpTwrHC
Listen
